My daughter Jordan and her boyfriend just returned from a weekend on the California coast.
They stopped at one of our favorite locations, the Santa Cruz beach boardwalk. We’ve gone there many times to take in the beautiful scenery, sample “cuisine” (like deep-fried Twinkies), and enjoy the rides.
And that means hitting the roller coaster.
I bring that up today because many investors feel that’s exactly where the market is taking them right now.
For many, looking at a chart of the S&P 500 of late gives them a very topsy-turvy feeling – to say the least.
This explains why I get the same question a lot these days. It goes like this: if there was one tech stock you’d never sell, what would it be?
For me, the answer is easy.
The one I have in mind is a great long-term play as well as a terrific place to park your cash – should you get stopped out of one of your favorite stocks amidst the volatility.
Tension in the Middle East and the South China Sea… a political mess at home… sky-high stock prices.
And here’s something else to worry about…
On Nov. 1, a Wall Street Journal headline warned about the “Consumer Confidence Conundrum.”
Here’s the worry: According to WSJ writer Chris Dieterich and the folks he talked, because consumer confidence is at its highest level since December 2000, it’s time to “add this to the list of reasons investors ought to be getting nervous.”
The reason: It may signal the bull market is coming to an end.
The treatment that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules created in the laboratory – isn’t going anywhere.
Yes, incredibly innovative treatments like T-cell therapy, microbiome therapies, and CRISPR gene editing are all having a huge impact on healthcare.
But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we’ll keep doing so for a long time to come.
The small molecule technique dates back to the 1890s, but that doesn’t mean innovation cannot happen within that field. Scientists are hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.
Meanwhile, I’ve turned up a small British company that’s using its artificial intelligence platform to discover promising small molecule treatments faster – and cheaper – than ever before.
I call it biointelligence.
It’s a perfect illustration of the “Convergence Economy” we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it’s like a formula in which 1 + 1 = 3… and often a lot more that.
Today, we’re going to learn all about this tiny company and its brand-new biointelligence technology.
This company is privately held – so if you ask, Wall Street will say you can’t invest in it.
But I’ve a way you can.
In fact, I’ve found two ways.
Both of them will lead you to outsized returns – and hefty dividends.
Donald Trump promises to create 25 million new jobs over the next decade with his economic plan.
And as we’ve been discussing over the past few weeks, I think that plan is a good one – and will be very good for tech companies and their investors.
However, there’s also this…
Robotics and artificial intelligence – “automation,” in a word – will eliminate tens of millions of jobs over that same stretch.
It makes many of us planning our retirement – trying to put together enough money and investments to guarantee that our “golden years” are prosperous – wonder how we’ll do it. Moreover, it makes us worry about our children’s and grandchildren’s futures.
How can anyone save or invest if they’re looking at a “jobless future”?
One way to do it – to not just survive but to thrive in this unknowable future – is to profit from the very automation technologies that are threatening humanity’s livelihood.
And to do that, you have to “pick” the best stocks in this sector.
I’ve just spotted such a company – one whose technology could to displace millions of “back office” workers in the coming years. You know, the folks doing data entry and handling the customer service lines.
Its technology is known as robotic process automation (RPA).
We’ve been talking a lot about artificial intelligence (AI) over the past few weeks.
About how the big brains at Google’s DeepMind AI system say they may have developed a memory system they’re calling a “differentiable neural computer” (DNC) and possibly unlocked the path to truly intelligent deep learning.
About how many of FacebookMessenger’s 1 billion users are using AI-enhanced “chatbots” for their customer-service needs – chatbots that may soon be handling bill paying, shopping, delivery, and a range of other tasks.